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Edited by Felix WeilandAbstract Adenosine deaminase isoenzyme 2 (ADA2) was iso-
lated from human pleural ﬂuid for the ﬁrst time. Molecular
and kinetic properties were characterized. It was shown that
the inhibitors of adenosine deaminase isoenzyme 1 (ADA1),
adenosine, and erithro-9-(2-hydroxy-3-nonyl)adenine (EHNA)
derivatives are poor inhibitors of ADA2. Comparison of the
interaction of ADA2 and ADA1 with adenosine and its deriva-
tive, 1-deazaadenosine, indicates that the isoenzymes have simi-
lar active centers. The absence of ADA2 inhibition by EHNA is
evidence of a diﬀerence of these active centers in a close environ-
ment. The possible role of Zn2+ ions and the participation of
acidic amino acids Glu and Asp in adenosine deamination cata-
lyzed by ADA2 were shown.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Adenosine deaminase (ADA, EC 3.5.4.4), a key enzyme in
the purine salvage pathway, catalyzes adenosine and 2 0-deoxy-
adenosine (2 0-dAdo) deamination to inosine and 2 0-deoxyino-
sine [1]. It is widely distributed in mammalian tissues, and
plays a critical role in proliferation, maturation and function
of lymphoid cells. Congenital ADA deﬁciency is accompanied
by accumulation of both intracellular and extracellular adeno-
sine (Ado), 2 0-dAdo, and their cytotoxic metabolites, by T-cell
depletion [2,3], and frequently is associated with severe com-
bined immunodeﬁciency syndrome [4]. As nucleoside related
drugs are now being used in clinics, the role of ADA has be-
come more signiﬁcant as a metabolic link that decreases the
lifetime of chemicals and hence shortening the time of their
therapeutic action.
Three molecular isoforms of human ADA are known: two
ADA1 forms – a low molecular weight form (34–43 kDa), a
high molecular complex with the ADA-binding protein (280–
300 kDa), and ADA2 (110 kDa). ADA1 isoforms are exten-Abbreviations: ADA1, adenosine deaminase isoenzyme 1; ADA2,
adenosine deaminase isoenzyme 2; Ado, adenosine; 2 0-dAdo, 20-
deoxyadenosine; C50, CM-Sephadex C50; EHNA, erithro-9-(2-hydro-
xy-nonyl)adenine; G200, Sephadex G200 superﬁne; 1-dAdo, 1-deaza-
adenosine; 3-dAdo, 3-deazaadenosine; 3-dEHNA, 3-deazaEHNA;
PMSF, phenylmethanesulphonylﬂuoride
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doi:10.1016/j.febslet.2004.11.109sively studied, but there is only limited information known
about ADA2.
ADA2 diﬀers from ADA1 by kinetic and immunochemical
properties and appears to be encoded by a separate genetic lo-
cus [1,5]. Its cellular source is not known and its physiological
role is poorly understood. ADA2 is responsible for a minor
part of total ADA activity in most tissues [6,7], but it is the pre-
dominant isoenzyme in the serum of normal subjects [8]. The
level of ADA2 activity in serum changes at some physiological
states, for example, levels were shown to decrease during nor-
mal pregnancy [9]. The increase of ADA2 activity during a
number of diseases (HIV-infection, AIDS, autoimmune abnor-
malities, and tuberculosis) implies that it is involved in their
development [10–14].
Using mathematical modeling, Gakis et al. [15] showed
that isoenzymes with diﬀerent aﬃnities for a substrate form
a homeostatic mechanism, constructing a biochemical en-
zyme–substrate system capable of preserving the cell against
environmentally induced changes. One example is the system
of two isoenzymes, ADA1 and ADA2, that have diﬀerent
aﬃnities for two cytotoxic substrates, Ado and 2 0-dAdo.
This system can guarantee optimal levels of these substrates
in the cell in spite of their continuous supply from the envi-
ronment.
The investigation of the ﬁne mechanism of ADA isoenzymes
interaction with the inhibitors is important for the design and
synthesis of new inhibitors as prospective as drugs to regulate
the isoenzymes at pathology. We have previously addressed
this question by studying the interaction of low molecular
ADA1 from diﬀerent tissues with derivatives of Ado and
erithro-9-(2-hydroxy-3-nonyl)adenine (EHNA) [16].
The diﬀerence in the physiological roles of ADA1 and
ADA2 is thought to be based on diversities in their molecular
and kinetic properties. The aim of the present study was the
isolation and puriﬁcation of ADA2 from human tuberculous
pleural ﬂuid, and a comparison of its molecular and kinetic
properties with ADA1 and ADA2 from human blood serum
[5,17].2. Materials and methods
2.1. Chemicals and devices
The tuberculous pleural ﬂuid was taken at the State Clinical Tuber-
culous Hospital of Armenia and stored at 12 C until use.
Ado, 2 0-dAdo, dipeptide Gly-Pro-pNA, BSA, ovalbumin, EHNA,
DTT, phenylmethanesulphonylﬂuoride (PMSF), Blue Dextran, Coo-
massie brilliant blue G-250 were purchased from Sigma (St. Louis,
MO, USA); CM-Sephadex C50 (C50) and Sephadex G200 superﬁne
(G200) were purchased from Pharmacia Biotech (Uppsala, Sweden);
chemicals for electrophoresis were from Reanal (Hungary). Deriva-
tives of Ado, 1-deazaadenosine (1-dAdo) and 3-deazaadenosineblished by Elsevier B.V. All rights reserved.
Fig. 1. ADA2 elution diagram from CM Sephadex C50 column at
application of linear gradient of KCl concentrations from 0.2 to 0.4 M
in buﬀer C. (--) – protein absorbance at 280 nm; (--) – ADA activity
determined in the presence of EHNA (absorbance at 625 nm).
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synthesized and provided by Prof. Gloria Cristalli (University of
Camerino, Italy). Adrenodoxin and cytochrome c were puriﬁed in
our laboratory.
Spectrophotometer measurements were carried out on Specord M-
40, (Carl Zeiss, Jena, Germany); cuvettes with light path 1, 2, 5, and
10 mm were used in thermostated cuvette holder. Centrifugation was
provided on centrifuges K-23 and K-24 (Heinz Janetzki KG, Leipzig,
Germany). Microconcentration tubes were from Centricon (Amicon,
Danvers, USA).
2.2. Enzyme puriﬁcation
Pleural ﬂuid was collected and immediately frozen. For enzyme puri-
ﬁcation 150 ml of pleural ﬂuid was thawed, homogenized in a Porter
glass homogenizer, and dialyzed for 15 h against 20 volumes of 20
mM potassium-phosphate buﬀer, pH 6.0 (buﬀer A), containing 1
mM PMSF, 1 mM EDTA and 20 lM ZnSO4 (buﬀer B). The precipi-
tate was removed by centrifugation at 10 000 · g 10 min. The superna-
tant was diluted 3-fold using buﬀer B without PMSF and EDTA
(buﬀer C) and applied to the C50 column (2.2 · 10 cm) that had been
equilibrated with buﬀer C. The column was sequentially washed with
buﬀer C, containing KCl at concentrations of 0.05, 0.1 and 0.2 M.
Afterwards, the fractions containing ADA2 activity were eluted using
linear gradient of KCl concentrations from 0.2 to 0.4 M in buﬀer C (to-
tal volume 300 ml). These fractions were diluted 10-fold with buﬀer C
without KCl, concentrated on a small column C50, and applied to a
gel-ﬁltration column of G200 (1.5 · 90 cm). The central fractions pos-
sessing ADA2 activity were concentrated by centrifugation in a micro-
concentrator at 3000 · g, 4 C. The obtained preparation was analyzed
on homogeneity by PAAG electrophoresis.
2.3. Enzyme assay
ADA activity was assayed by evaluation of liberated ammonia using
the colorimetric method of Chaney and Marbach [18] described in our
previous study [19]. Brieﬂy, each of the two identical incubation mix-
tures contained in 350 ll: 40 mM phosphate buﬀer, pH 6.0, the appro-
priate amount of a sample, and 40 lM EHNA in one of these parallel
mixtures. After preincubation at 25 C for 20 min, the enzymatic
deamination was initiated by addition of 150 ll of Ado stock solution
(20 mM in distilled water) and incubated for 40 min at 37 C. The reac-
tion was stopped by addition of 1 ml of both the phenol–nitroprusside
and hypochlorite reagents for ammonia determination. The amount of
ammonia was calculated based on the absorption at 625 nm, using
ammonium sulfate as a standard. The resulting value for the assay
mixture without EHNA was deﬁned as total ADA activity. The value
for the EHNA containing parallel mixture was deﬁned as the activity
of ADA2. The diﬀerence between these two values was deﬁned as
activity of ADA1.
2.4. Determination of pH-optimum
The dependence on pH at the range of 3.5–8.5 of ADA2 activity in
the reaction of adenosine deamination was studied. 40 mM succinate–
HCl buﬀers (pH 3.5–5.5) and 40 mM K–Na phosphate buﬀers (pH
5.5–8.5) were used. The assay mixture was preincubated at the appro-
priate pH before beginning the enzymatic reaction by addition of sub-
strate (see above).
2.5. Determination of inhibition constant
The value of the inhibition constant, Ki, was determined by using the
Dixon graphical approach [20]: reciprocal activity was plotted as a
function of inhibitor concentration at two diﬀerent concentrations of
substrate (usually, 3 and 6 mM). The Ki for competitive inhibitor
was determined as the negative value of the abscissa of interception
of these two linear plots.
2.6. Other methods
Electrophoresis in 7.5% PAAG at room temperature was conducted
in accordance with the standard procedure of Reisfeld for alkaline pro-
teins [21]. 20–50 lg of protein sample was applied to each row. After
electrophoresis (55 mA, 3 h), the gels were ﬁxed in 10% TCA and visu-
alized with Coomassie Brilliant Blue G 250.
Protein was determined by the method of Bradford [22] with BSA as
a standard.The kinetic and statistical analyses were performed with GraFit [23]
and InStat (version 3 for Windows) software. All parameters were esti-
mated based on at least three independent puriﬁcation procedures.3. Results and discussion
3.1. Puriﬁcation of ADA2 from pleural ﬂuid
We have previously shown that the ADA2 isoform is
responsible for up to 80% of the total ADA activity in pleural
eﬀusions of tuberculous patients [24,25]. Therefore, we used
pleural ﬂuid as the source of this isoenzyme.
As the ﬁrst step of ADA2 puriﬁcation, cation-exchange
chromatography on C50 column was used. In the fractions
that passed through the column during application of dialyzed
pleural ﬂuid and washing with buﬀer C, the ADA activity was
inhibited by EHNA, a well known selective inhibitor of
ADA1. These fractions were collected as isoenzyme ADA1.
Contaminating protein without ADA activity was removed
at washing the column with buﬀer C, containing 0.05, 0.1,
and 0.2 M KCl. The elution diagram of the KCl concentration
gradient between 0.2 and 0.4 M in buﬀer C is shown in Fig. 1.
The deaminating activity in these fractions was not inhibited
by EHNA and we collected it as the ADA2 isoenzyme. As this
step completely separated the two ADA isoenzymes, no fur-
ther testing of the protein preparation activity with EHNA
was required.
The central active fractions were collected, concentrated on
a second small column of C50, and applied to a gel-ﬁltration
column of G200. PAAG electrophoresis of central fractions
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tion (Fig. 2, Table 1).
In contrast to ADA1, ADA2 appeared more labile. It dras-
tically lost enzyme activity upon freezing. Taken together with
the low level of ADA2 in most tissues, this instability also pre-
sents diﬃculties in both the puriﬁcation and study of the
catalytic properties. However, it is noteworthy that our exper-
iments proved that the presence of 20 lM zinc ions in buﬀers
improved the stability of ADA2 during puriﬁcation. This
observation assumes the involvement of Zn2+ ions in ADA2
active center structure, similar to ADA1 [26] and AMP deam-
inase [27].
3.2. Molecular mass
The gel-ﬁltration on a G200 column was used for evaluation
of molecular mass of ADA2. The column was calibrated using
BSA (M.m. of dimer –134 kDa and of monomer – 67 kDa),
ovalbumin (44 kDa), adrenodoxin (14 kDa) and cytochrome c
(12 kDa) as markers. The void volume (V0) of column was
evaluated with blue dextran (M.m. 106Da) and the dependence
of ratio of the markers elution volumes to V0 versus the loga-
rithm of molecular mass was plotted. From the linear graph of
this dependence (not shown), the M. m. of ADA2 was esti-
mated as 107 kDa. This value corresponds to the known value
for the enzyme from human blood serum, 110 kDa [5].
3.3. Kinetic parameters
We compared the enzymatic catalysis of deamination of two
substrates, Ado and 2 0-dAdo.Both of these deamination reac-
tions ﬁt theMichaelis–Menten rule. The double reciprocal lin-Fig. 2. PAAG electrophoresis of puriﬁed ADA2 from human pleural
ﬂuid.
Table 1
Stages of ADA2 puriﬁcation
Puriﬁcation step Total volume (ml) Total protein (mg) Activity of A
Total (nmol/m
Pleural exudates 150 6800 1100
Dialysis 160 2880 1100
C50 16 0.8 169
G-200 9.7 0.25 146ear plots of activity vs substrate concentration (Lineweaver
and Burk plots) allowed evaluation of the Michaelis parame-
ters, kcat and Km (Table 2). The Michaelis coeﬃcient of
ADA2 for Ado, Km = 1.48 mM, was by 1.5 orders of magni-
tude higher than Km of ADA1 (0.1 mM [28]), and is close to
the value for ADA2 from human serum [17]. Km values for
Ado and 2 0-dAdo are practically the same. However, the high-
er value of catalytic eﬃciency, kcat/Km, for Ado deamination in
comparison with that for 2 0-dAdo (last column in Table 2)
makes it a more preferable substrate for ADA2.
3.4. pH-optimum
In Fig. 3, the dependence on pH of ADA2 activity in the
deamination of Ado is shown. It demonstrates the broad
pH-optimum of isoenzyme activity at pH ranges between 5.5
and 7.0. The bell-shaped pH-proﬁle drastically decreases at
higher pH, remaining gently sloping at the acidic region. It is
worth noting that the pH-dependence of low molecular weight
ADA1, having a broad range of pH-optimum between 7.0 and
8.5, shows a more drastic decrease to the acidic pH [29].
The obtained pH-proﬁle was analyzed using GraFit soft-
ware, and two pKa values on the gently sloping acidic side,
4.1 and 4.5, and one on the basic side, 7.8, were evaluated.
The pKa values in the acidic side allow us to suggest that
Asp and Glu with pKa 3.9 and 4.3, respectively, participate
in adenosine deamination catalyzed by ADA2. The same had
been shown for ADA1 (Glu217, Asp 295) by crystallographic
investigations [30]. Moreover, the lower value of pKa for
ADA2 compared with the value for ADA1 (5.6 [29]) led us
to conclude that the role of these amino acids in ADA2 cata-
lyzed reaction is more substantial than in the case of ADA1.
3.5. Interaction with the known inhibitors of ADA1
In this work, we tested the inhibition of ADA2 by two sub-
strate analogs, 1-dAdo and 3-dAdo, and by EHNA and its
derivative, 3-dEHNA.
The Ki value of 1-dAdo for ADA2 (80 lM, Table 2) was 1.5
orders of magnitude higher than for ADA1 (2–5 lM, [16]).
The Km values for ADA2 and ADA1 also diﬀered by 1.5 or-
ders of magnitude (1.5 mM, Table 2, and 0.1 mM [28], respec-
tively). We consider the similarity of 1.5 orders of magnitude
between the Km values of adenosine and the Ki values of 1-
dAdo for the two isoenzymes to be indirect evidence of similar-
ity in the structure of the active centers of ADA1 and ADA2.
A poor inhibitor of ADA1, 3-dAdo (Ki = 1 · 103 M), did not
inhibit ADA2 in our experimental conditions, conﬁrming our
suggestion.
The stronger inhibitors of ADA1 EHNA (Ki = 25 ·
108 M) and 3-dEHNA (Ki = 11.2 · 107 M) did not inhibit
ADA2. This provides evidence of the essential diﬀerence in
binding sites of EHNA in two ADA isoenzymes: the hydro-
phobic site on ADA1 that is required for complex formationDA2 Extent of puriﬁcation Yield (%)
in) Speciﬁc (nmol/min/mg)
0.16
0.38 2.4 100
203 1256 15
586 3615 13
Fig. 3. The dependence of ADA2 activity on pH.
Table 2
Steady-state kinetic parameters for deamination of substrates by ADA2 and for its interaction with inhibitors
Substrate (inhibitor) Km (mM) Ki (lM) kcat (s
1) kcat/Km (mM
1 s1)
Adenosine 1.48 ± 0.12a – 13.3 ± 1.1 8.98
2 0-dAdo 1.55 ± 0.13 – 3.3 ± 0.21 2.15
1-dAdo – 80 ± 10 –
3-dAdo Non-inhibited
EHNA Non-inhibited
3-dEHNA Non-inhibited
aThe parameters are presented as means of at least three independant determinations ±S.E.
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ADA2.4. Conclusion
For the ﬁrst time, ADA2 from human pleural ﬂuid has been
isolated and characterized. Themolecular and kinetic properties
were studied, and their identity tomain characteristics of ADA2
from human plasma is demonstrated. The diﬀerences in interac-
tion of ADA1 and ADA2 with Ado and its derivative 1-dAdo
suggest the similarity of structure of their active centers. The fail-
ure of a strong ADA1 inhibitor, EHNA, to inhibit ADA2 sug-
gests the absence of hydrophobic site in ADA2 preventing this
compound binding. The probability of Zn2+ ions involvement
in ADA2 active center structure and the importance of amino
acids Glu and Asp in ADA2 catalyzed reaction are suggested.
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